GH-axis research
CJC-1295 with DAC
Lyophilized endocrine-signaling research peptide for systems review
CJC-1295 with DAC is a longer-acting GHRH analog studied for extended GH-axis signaling and albumin-binding pharmacology.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updates仅供实验室研究使用。不适用于人类或兽医用途。并非旨在诊断、治疗、治愈、减轻或预防疾病。
Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.
Packed for transit stability with order support available for warm-weather routes.
Batch-linked certificate support is available through the documentation desk.
研究背景
CJC-1295 with DAC 研究资料
CJC-1295 with DAC is a longer-acting GHRH analog designed to extend exposure through drug-affinity-complex chemistry and albumin binding. Research examines pharmacokinetics, prolonged GH and IGF-1 marker changes, pituitary signaling, and how sustained activity differs from shorter GHRH analogs. It is distinct from CJC-1295 No DAC, which is used for shorter pulse-pattern comparisons, and from ipamorelin or GHRP compounds, which signal through the ghrelin receptor. This version is most relevant when half-life extension is central to the study design. Published pharmacology for named investigational material does not independently verify the sequence, purity, or performance of a catalog batch.
Molecular class
DAC-modified GHRH analog
Sequence / composition
A substituted GHRH 1-29-style peptide linked to a Drug Affinity Complex designed for albumin association.
Research design note
The DAC attachment, rather than the name alone, distinguishes the expected exposure profile from a no-DAC construct.
拟议机制
A GHRH analog containing a drug-affinity-complex group designed to form a covalent bond with serum albumin. Albumin binding reduces clearance and prolongs GHRH-receptor stimulation, increasing GH secretion and downstream IGF-1.
研究中报告的作用
- Healthy-adult studies reported dose-dependent increases in GH lasting several days and increases in IGF-1 lasting approximately one to two weeks after studied exposures.
- Repeated exposure in pharmacology studies produced sustained elevation of GH and IGF-1 without eliminating pulsatile secretion.
- Reported observations included injection-site reactions and endocrine changes expected from prolonged GH-axis stimulation.
常见研究终点
Albumin binding, half-life, GHRH receptor activity, GH pulse pattern, integrated GH exposure, IGF-1, glucose, insulin, binding proteins, pharmacokinetics, and adverse events.
证据与局限
Controlled human pharmacology exists for the original investigational CJC-1295 with DAC. Product sequence and DAC chemistry must match before those data are considered relevant.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
Where can I find product documentation?
Contact support with the product name and any relevant order or batch reference to request available documents.
How can I compare pack options?
Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.
Keep comparing
Compare other catalog records.
Explore related research materials. These are not a combined-use recommendation.
-
GH axis
CJC-1295 No DAC
CJC-1295 No DAC is a short-acting GHRH analog studied as a pituitary GH-axis signaling reference.
- 形式
- Lyophilized powder
- 数量
- 5 mg